Welcome to Tumor-Specific NeoAntigen database (TSNAdb v1.0)!

        Tumor-specific neoantigens have attracted much attention since they can be used as biomarkers to predict therapeutic effects of immune checkpoint blockade therapy and potential targets for cancer immunotherapy.

        TNSAdb v1.0 is developed based on pan-cancer immunogenomic analyses of somatic mutation data and human leukocyte antigen (HLA) allele information for 16 tumor types with 7748 tumor samples from The Cancer Genome Atlas (TCGA) and The Cancer Immunome Atlas (TCIA). We predicted binding affinities between mutant/wild-type peptides and HLA class I molecules by NetMHCpan 2.8 (4.0) and presented detailed information of 3,707,562 (1,298,601) potential neoantigens generated by somatic mutations of all tumor samples.

TissueProjectNo. of sampleNo. of HLA allelesNo. of mutationNo. of neoantigen
predicted by NetMHCpan 2.8
No. of neoantigen
predicted by NetMHCpan 4.0
BladderBLCA4081064953718275665186
BrainGBM15182117374752115117
BreastBRCA9821244189515905956197
CervixCESC2861193155811155838787
ColorectalCOAD READ531133108520401274131513
Head and NeckHNSC4951073711413582248526
KidneyKICH KIRC KIRP681124176766649223648
LiverLIHC358115190737544924392
LungLUAD LUSC999120143449554133194553
OvaryOV30598189387095525148
PancreasPAAD16673112143626616092
ProstatePRAD493102122624904616380
SkinSKCM466103129201510319190139
StomachSTAD4111216917226235685283
ThyroidTHCA4881202779109043721
UterusUCEC5281532680621033652363919